Examining the effects of Baricitinib in patients with rheumatoid arthritis
Efficacy and Safety of Baricitinib in Rheumatoid Arthritis Patients Compared With Those Treated by Biologics or Tofacitinib
This study is testing if Baricitinib works better than other treatments for rheumatoid arthritis to help people manage their symptoms over a year.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Shinshu University Academic / other |
| Drugs / interventions | Baricitinib, Tofacitinib |
| Locations | 1 site (Matsumoto, Nagano) |
| Trial ID | NCT03755466 on ClinicalTrials.gov |
What this trial studies
This study evaluates the efficacy and safety of Baricitinib compared to biologics and Tofacitinib in patients with rheumatoid arthritis over a 12-month period. Participants will be divided into three groups, each receiving one of the treatments for the duration of the study. The primary focus is to assess the effectiveness of these medications in managing symptoms and any adverse events that may arise during treatment. The study aims to provide insights into the best therapeutic options for rheumatoid arthritis patients.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with rheumatoid arthritis who meet the inclusion criteria.
Not a fit: Patients who are not diagnosed with rheumatoid arthritis or those who are allergic to the study medications will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options for patients suffering from rheumatoid arthritis.
How similar studies have performed: Other studies have shown promising results with similar treatments for rheumatoid arthritis, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * RA patients Exclusion Criteria: * Not RA patients * RA patients who are allergic to the drugs, refused to do this research, or who are pregnant
Where this trial is running
Matsumoto, Nagano
- Yukio Nakamura — Matsumoto, Nagano, Japan (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.